Literature DB >> 25512148

A founder EIF2AK4 mutation causes an aggressive form of pulmonary arterial hypertension in Iberian Gypsies.

J Tenorio1,2, P Navas3,4, E Barrios5, L Fernández1,2, J Nevado1,2, C A Quezada4, M López-Meseguer6,7,8, P Arias1,2, R Mena2, J L Lobo9, C Alvarez10, K Heath1,2, P Escribano-Subías3,4, P Lapunzina1,2.   

Abstract

Pulmonary arterial hypertension (PAH) is a pathological condition characterized by a persistent and progressive elevation of pulmonary vascular resistance with devastating consequences if untreated. In the past recent years, several genes have been related to PAH, however, the molecular defect remains unknown in a significant proportion of patients with familial PAH (∼20%). During the past few years, we have observed that PAH shows a particular behavior in Iberian Gypsies, with more aggressive course and frequently affecting multiple members of the same family. We studied five Gypsy families in whom at least one individual from each family developed a severe form of PAH and in whom no mutation had been identified in the common genes. We applied SNP-array-based homozygosity mapping in three families and obtained, among others, one of which included the gene EIF2AK4, recently reported in patients with PAH from group-1' pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH). Subsequently, we sequenced EIF2AK4 and found a homozygous mutation in all five families: c.3344C>T(p.P1115L). The majority of our patients required early lung transplantation. Hence, this mutation appeared with a more severe phenotype than previously reported for other EIF2AK4 mutations. The finding of this novel mutation is important for genetic counseling and calculation of population recurrence risks.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  EIF2AK4; Gypsies; SNP-arrays; autosomal recessive disease; c.3344C>T; pulmonary arterial hypertension

Mesh:

Substances:

Year:  2015        PMID: 25512148     DOI: 10.1111/cge.12549

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  13 in total

Review 1.  Molecular basis of the association between transcription regulators nuclear respiratory factor 1 and inhibitor of DNA binding protein 3 and the development of microvascular lesions.

Authors:  Christian Michael Perez; Quentin Felty
Journal:  Microvasc Res       Date:  2022-02-07       Impact factor: 3.514

2.  A Semiconductor Chip-Based Next Generation Sequencing Procedure for the Main Pulmonary Hypertension Genes.

Authors:  Juan Gómez; Julian R Reguero; Celso Alvarez; Manuel R Junquera; Ana Arango; César Morís; Eliecer Coto
Journal:  Lung       Date:  2015-04-28       Impact factor: 2.584

3.  EIF2AK4 mutation as "second hit" in hereditary pulmonary arterial hypertension.

Authors:  Christina A Eichstaedt; Jie Song; Nicola Benjamin; Satenik Harutyunova; Christine Fischer; Ekkehard Grünig; Katrin Hinderhofer
Journal:  Respir Res       Date:  2016-11-04

4.  Rapid disease progress in a PVOD patient carrying a novel EIF2AK4 mutation: a case report.

Authors:  Xiaofang Zeng; Fan Chen; Anandharajan Rathinasabapathy; Tangzhiming Li; Agila Adnan Ali Mohammed Mohammed; Zaixin Yu
Journal:  BMC Pulm Med       Date:  2020-07-06       Impact factor: 3.317

Review 5.  Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects.

Authors:  Rajiv D Machado; Laura Southgate; Christina A Eichstaedt; Micheala A Aldred; Eric D Austin; D Hunter Best; Wendy K Chung; Nicola Benjamin; C Gregory Elliott; Mélanie Eyries; Christine Fischer; Stefan Gräf; Katrin Hinderhofer; Marc Humbert; Steven B Keiles; James E Loyd; Nicholas W Morrell; John H Newman; Florent Soubrier; Richard C Trembath; Rebecca Rodríguez Viales; Ekkehard Grünig
Journal:  Hum Mutat       Date:  2015-10-12       Impact factor: 4.878

Review 6.  Pulmonary capillary hemangiomatosis: a focus on the EIF2AK4 mutation in onset and pathogenesis.

Authors:  Lijiang Ma; Ruijun Bao
Journal:  Appl Clin Genet       Date:  2015-08-07

7.  A view on clinical genetics and genomics in Spain: of challenges and opportunities.

Authors:  Teresa Pàmpols; Feliciano J Ramos; Pablo Lapunzina; Ignasi Gozalo-Salellas; Luis A Pérez-Jurado; Aurora Pujol
Journal:  Mol Genet Genomic Med       Date:  2016-07-18       Impact factor: 2.183

Review 8.  The integrated stress response in pulmonary disease.

Authors:  Giulia Emanuelli; Nikou Nassehzadeh-Tabriz; Nick W Morrell; Stefan J Marciniak
Journal:  Eur Respir Rev       Date:  2020-10-01

9.  Novel EIF2AK4 mutations in histologically proven pulmonary capillary hemangiomatosis and hereditary pulmonary arterial hypertension.

Authors:  Ossama K Abou Hassan; Wiam Haidar; Mariam Arabi; Hadi Skouri; Fadi Bitar; Georges Nemer; Imad Bou Akl
Journal:  BMC Med Genet       Date:  2019-11-11       Impact factor: 2.103

10.  Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension.

Authors:  Charaka Hadinnapola; Marta Bleda; Matthias Haimel; Nicholas Screaton; Andrew Swift; Peter Dorfmüller; Stephen D Preston; Mark Southwood; Jules Hernandez-Sanchez; Jennifer Martin; Carmen Treacy; Katherine Yates; Harm Bogaard; Colin Church; Gerry Coghlan; Robin Condliffe; Paul A Corris; Simon Gibbs; Barbara Girerd; Simon Holden; Marc Humbert; David G Kiely; Allan Lawrie; Rajiv Machado; Robert MacKenzie Ross; Shahin Moledina; David Montani; Michael Newnham; Andrew Peacock; Joanna Pepke-Zaba; Paula Rayner-Matthews; Olga Shamardina; Florent Soubrier; Laura Southgate; Jay Suntharalingam; Mark Toshner; Richard Trembath; Anton Vonk Noordegraaf; Martin R Wilkins; Stephen J Wort; John Wharton; Stefan Gräf; Nicholas W Morrell
Journal:  Circulation       Date:  2017-09-28       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.